Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By
Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA
Presented by
Edward Garon David Geffen School of Medicine at UCLA, CA, USA
Conference
ELCC 2022
Trial
Phase 3, POSEIDON
Doi
https://doi.org/10.55788/1f78466a
The phase 3 POSEIDON study previously showed that the addition of immunotherapy (durvalumab or durvalumab/tremelimumab) to chemotherapy numerically improved survival of patients with metastatic non-small cell lung cancer (NSCLC). Patient-reported outcomes now indicate that deterioration of health-related quality of life (QoL) is delayed. Immunotherapy is an important treatment modality for metastatic NSCLC. Dual blockade of PD-1/PD-L1 and CTLA-4 pathways may provide additive or synergistic effects. In the phase 3 POSEIDON trial (NCT03164616), first-line durvalumab plus chemotherapy significantly improved progression-free survival (PFS) versus chemotherapy alone in patients with metastatic NSCLC, with a positive trend for overall survival (OS) improvement that did not reach statistical significance [1]. In addition, first-line tremelimumab plus durvalumab plus chemo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on